https://prabadinews.com/
  • October 8, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL

FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL

The CRL states that the STARGLO data do not provide sufficient evidence to support the second-line indication in the US patient population.

administrator

Related Articles